Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.

AIM To evaluate the best diagnostic technique and risk factors of the human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) infection in inflammatory bowel disease (IBD). METHODS A cohort of 40 IBD patients (17 refractory) and 40 controls underwent peripheral blood and endoscopic colonic mucosal sample harvest. Viral infection was assessed by quantitative real-time polymerase chain reaction and immunohistochemistry, and correlations with clinical and endoscopic indexes of activity, and risk factors were investigated. RESULTS All refractory patients carried detectable levels of HCMV and/or EBV mucosal load as compared to 13/23 (56.5%) non-refractory and 13/40 (32.5%) controls. The median DNA value was significantly higher in refractory (HCMV 286 and EBV 5.440 copies/10(5) cells) than in non-refractory (HCMV 0 and EBV 6 copies/10(5) cells; P < 0.05 and < 0.001) IBD patients and controls (HCMV and EBV 0 copies/10(5) cells; P < 0.001 for both). Refractory patients showed DNA peak values ≥ 10(3) copies/10(5) cells in diseased mucosa in comparison to non-diseased mucosa (P < 0.0121 for HCMV and < 0.0004 for EBV), while non-refractory patients and controls invariably displayed levels below this threshold, thus allowing us to differentiate viral colitis from mucosal infection. Moreover, the mucosal load positively correlated with the values found in the peripheral blood, whilst no correlation with the number of positive cells at immunohistochemistry was found. Steroid use was identified as a significant risk factor for both HCMV (P = 0.018) and EBV (P = 0.002) colitis. Finally, a course of specific antiviral therapy with ganciclovir was successful in all refractory patients with HCMV colitis, whilst refractory patients with EBV colitis did not show any improvement despite steroid tapering and discontinuation of the other medications. CONCLUSION Viral colitis appeared to contribute to mucosal lesions in refractory IBD, and its correct diagnosis and management require quantitative real-time polymerase chain reaction assay of mucosal specimens.

[1]  B. Pinsky,et al.  Diagnosis of Congenital CMV Using PCR Performed on Formalin-fixed, Paraffin-embedded Placental Tissue , 2013, The American journal of surgical pathology.

[2]  A. Ford,et al.  Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.

[3]  Annette S. Kim,et al.  Hemophagocytic Lymphohistiocytosis An Update on Diagnosis and Pathogenesis , 2013 .

[4]  A. Tsakris,et al.  Inflammatory Bowel Disease Exacerbation Associated With Epstein-Barr Virus Infection , 2013, Diseases of the colon and rectum.

[5]  M. Michaels,et al.  Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. Fishman.  Overview: Cytomegalovirus and the Herpesviruses in Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[8]  F. Baldanti,et al.  Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  B. Pozzetto,et al.  Management of cytomegalovirus infection in inflammatory bowel diseases. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  E. Arbustini,et al.  Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients. , 2012, The new microbiologica.

[11]  M. Gulley,et al.  Epstein-Barr Virus Infection Is Common in Inflamed Gastrointestinal Mucosa , 2012, Digestive Diseases and Sciences.

[12]  P. Lamprecht,et al.  Longitudinal analysis of frequency and reactivity of epstein–barr virus‐specific T lymphocytes and their association with intermittent viral reactivation , 2012, Journal of medical virology.

[13]  L. Peyrin-Biroulet,et al.  Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative Colitis , 2011, The American Journal of Gastroenterology.

[14]  D. Shih,et al.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. , 2011, World journal of gastroenterology.

[15]  S. Hanauer,et al.  Assessing Response and Loss of Response to Biological Therapies in IBD , 2011, The American Journal of Gastroenterology.

[16]  D. Rubin,et al.  Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents , 2010, Inflammatory bowel diseases.

[17]  M. Diebold,et al.  Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases , 2010, Journal of medical virology.

[18]  A. Moss,et al.  Cytomegalovirus in inflammatory bowel disease: Pathogen or innocent bystander? , 2010, Inflammatory bowel diseases.

[19]  H. Herfarth,et al.  Evaluation of a Non-invasive Method to Detect Cytomegalovirus (CMV)-DNA in Stool Samples of Patients with Inflammatory Bowel Disease (IBD): A Pilot Study , 2010, Digestive Diseases and Sciences.

[20]  J. Wedemeyer,et al.  Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  M. I. Nassar,et al.  Acute Cytomegalovirus Infection Is a Risk Factor in Refractory and Complicated Inflammatory Bowel Disease , 2009, Digestive Diseases and Sciences.

[22]  H. Sokol,et al.  Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye , 2009, Digestive Diseases.

[23]  H. Tilg,et al.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[24]  E. Oldfield,et al.  Gastrointestinal cytomegalovirus disease in the immunocompromised patient , 2008, Current gastroenterology reports.

[25]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[26]  T. Chiba,et al.  Usefulness of quantitative real‐time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies , 2007, Inflammatory bowel diseases.

[27]  C. Sabin,et al.  Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation , 2007, Transplantation.

[28]  M. Daperno,et al.  Infliximab and the risk of latent viruses reactivation in active Crohn's disease , 2007, Inflammatory bowel diseases.

[29]  B. Lashner,et al.  Cytomegalovirus Colitis Complicating Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[30]  A. Utsunomiya,et al.  Epstein–Barr virus‐associated enteritis with multiple ulcers after stem cell transplantation: First histologically confirmed case , 2006, Pathology international.

[31]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[32]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[33]  Y. Bouhnik,et al.  Cytomegalovirus infection in patients with active inflammatory bowel disease. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[34]  F. Watzinger,et al.  Real-Time Quantitative PCR Assays for Detection andMonitoring of Pathogenic Human Viruses in ImmunosuppressedPediatricPatients , 2004, Journal of Clinical Microbiology.

[35]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[36]  D. Hommes,et al.  The Pathogenicity of Cytomegalovirus in Inflammatory Bowel Disease: A Systematic Review and Evidence-based Recommendations for Future Research , 2004, Inflammatory bowel diseases.

[37]  D. Helbling,et al.  Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. , 2002, European journal of gastroenterology & hepatology.

[38]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  G. Viale,et al.  Evidence of Epstein-Barr virus infection in ulcerative colitis. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  G. Pietrosi,et al.  Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis , 2001, American Journal of Gastroenterology.

[41]  K. Okita,et al.  Epstein-Barr virus infection of the colon with inflammatory bowel disease. , 1999 .

[42]  I. Ojanguren,et al.  Cytomegalovirus infection in patients with inflammatory bowel disease , 1999, American Journal of Gastroenterology.

[43]  B. A. Forbes,et al.  The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system. , 1990, The Journal of infectious diseases.

[44]  G. Hunninghake,et al.  Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. , 1990, The Journal of clinical investigation.

[45]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[46]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[47]  J. H. Baron,et al.  Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.

[48]  Kristin M. Post,et al.  qPCR increases sensitivity to detect cytomegalovirus in formalin-fixed, paraffin-embedded tissue of gastrointestinal biopsies. , 2014, Human pathology.

[49]  I. Grishina,et al.  Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[50]  G. Gaidano,et al.  Transplant Lymphoproliferative Disorders: Role Infection, Genetic Lesions and Antigen Stimulation he Disease , 2009 .

[51]  M. J. Burns.  The immunocompromised patient. , 1989, Critical care nursing clinics of North America.